Home → E-shop → Antiviral compounds → Abacavir – CAS 136470-78-5

Abacavir – CAS 136470-78-5

Abacavir – CAS 136470-78-5 is synthesised by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

97%+

Package contents

Abacavir

This compound is for research use only. We do not sell to patients.

Amount

1 g	€ 300	Stock
5 g	€ 500	Stock
Do you want custom amount?			Custom amount

Amount

1 g

€ 300

Stock

5 g

€ 500

Stock

Do you want custom amount?

Custom amount

Characterisation

CAS: 136470-78-5

IUPAC name: [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol

Other names: Abacavir

Molecular weight: 286.33 g/mol

Molecular formula: C₁₄H₁₈N₆O

InChI: InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1

Description

Abacavir is a 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol, with the pro-R hydrogen at the 4-position replaced by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. It is a nucleoside analogue reverse transcriptase inhibitor (NRTI) having antiretroviral effectiveness against HIV. It is used in combination therapy with other antiretrovirals to treat HIV infection. It functions as an HIV-1 reverse transcriptase inhibitor, an antiviral medication, and a drug allergen.

Chemicals are distributed worldwide

Buy Abacavir now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Foster, R. H., & Faulds, D. (1998). Abacavir. Drugs, 55(5).
Hervey, P. S., & Perry, C. M. (2000). Abacavir: a review of its clinical potential in patients with HIV infection. Drugs, 60, 447-479.
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., … & Nichols, G. (2013). Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. New England Journal of Medicine, 369(19), 1807-1818.